Articles Tagged With: Corticosteroids
-
Corticosteroids as Adjuvant Therapy for Community-Acquired Pneumonia
This article aims to provide a summative analysis of the existing medical literature surrounding the effect of steroid treatment on community acquired pneumonia, including recent updates.
-
Adjuvant Systemic Corticosteroid Therapy in Hospitalized Patients with Community-Acquired Pneumonia
In this meta-analysis, all-cause mortality, ICU admission, and incidence of adverse events were similar in patients who received corticosteroids compared to standard care. However, the corticosteroid therapy group recorded a lower incidence of progression to mechanical ventilation.
-
Steroids and Pneumonia — So Meta?
In a multicenter, randomized, placebo-controlled trial, hydrocortisone reduced mortality in patients with severe community-acquired pneumonia.
-
Adjuvant Systemic Corticosteroid Therapy in Hospitalized Patients with Community-Acquired Pneumonia
This systematic review and meta-analysis of 16 randomized controlled trials (RCTs) studied the use of adjunctive corticosteroid therapy in community-acquired pneumonia. All-cause mortality, intensive care unit admission, and incidence of adverse events were similar in patients who received corticosteroids compared to standard care. However, the corticosteroid therapy group had a lower incidence of progression to mechanical ventilation.
-
Adjunctive Corticosteroids in Patients with Severe Community-Acquired Pneumonia
A double-blind, randomized, controlled trial conducted at 31 French medical centers demonstrated adult patients with severe community-acquired pneumonia who were given hydrocortisone had a lower risk of death by day 28 compared with those who received placebo.
-
WHO: Corticosteroids OK for Children with Multisystem Inflammatory Syndrome
International group updates guidelines for treating young patients with this rare-but-serious COVID-19-related complication.
-
Is There a Role for Immunomodulatory Therapy in COVID-19 Cytokine Storm?
In this retrospective analysis of COVID-19 patients hospitalized with cytokine storm, the use of corticosteroids combined with tocilizumab was associated with superior survival when compared to no immunomodulatory treatment; a combination of corticosteroids and anakinra; or corticosteroids, tocilizumab, or anakinra alone. Patients who received corticosteroids, either alone or in combination with anakinra, also experienced lower hospital mortality compared to no treatment. -
A Review of Current Therapeutics for Severe COVID-19 Pneumonia
The aim of this special feature is to review therapeutic options for hospitalized patients with COVID-19 pneumonia.
-
Corticosteroid Bursts and Subsequent Sepsis
Short-term (< 14 days) administration of oral corticosteroids is associated with an increased risk of adverse events, including an approximately two-fold risk of sepsis.
-
COVID-19 and Steroids: Is There a Consensus on the Controversy?
A retrospective, single-center cohort study among 201 adults admitted with COVID-19 pneumonia revealed that risk factors associated with the development of acute respiratory distress syndrome (ARDS) and progression from ARDS to death included older age, neutrophilia, organ dysfunction, and coagulation derangement. Treatment with methylprednisolone may be beneficial for these patients.